ArticleMolecular and cellular biology1991
Identification of a matrix-associated region 5' of an immunoglobulin heavy chain variable region gene.
Article in Molecular and cellular biology, 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 58 citations in OpenAlex.
- ARID3a from the ARID family: structure, role in autoimmune diseases and drug discovery.Acta pharmacologica Sinica · 2023Review
- New Frontiers: ARID3a in SLE.Cells · 2019Review
- Positional specificity of different transcription factor classes within enhancers.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Competitive Promoter-Associated Matrix Attachment Region Binding of the Arid3a and Cux1 Transcription Factors.Diseases (Basel, Switzerland) · 2017Article
- Human effector B lymphocytes express ARID3a and secrete interferon alpha.Journal of autoimmunity · 2016Article
- The Transcription Factor ARID3a Is Important for In Vitro Differentiation of Human Hematopoietic Progenitors.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- The Bright Side of Hematopoiesis: Regulatory Roles of ARID3a/Bright in Human and Mouse Hematopoiesis.Frontiers in immunology · 2014Review
- The ARID family transcription factor bright is required for both hematopoietic stem cell and B lineage development.Molecular and cellular biology · 2011Article
- Loss of Bright/ARID3a function promotes developmental plasticity.Stem cells (Dayton, Ohio) · 2010Article
- Signalling of the BCR is regulated by a lipid rafts-localised transcription factor, Bright.The EMBO journal · 2009Article
- SUMOylation of DRIL1 directs its transcriptional activity towards leukocyte lineage-specific genes.PloS one · 2009Article
- Bright/ARID3A contributes to chromatin accessibility of the immunoglobulin heavy chain enhancer.Molecular cancer · 2007Article
- A comparative study of S/MAR prediction tools.BMC bioinformatics · 2007Article
- Anti-nuclear antibody production and autoimmunity in transgenic mice that overexpress the transcription factor Bright.Journal of immunology (Baltimore, Md. : 1950) · 2007Article
- A regulated nucleocytoplasmic shuttle contributes to Bright's function as a transcriptional activator of immunoglobulin genes.Molecular and cellular biology · 2006Article
- Bruton's tyrosine kinase regulates immunoglobulin promoter activation in association with the transcription factor Bright.Molecular and cellular biology · 2005Article
- SMAR1 and Cux/CDP modulate chromatin and act as negative regulators of the TCRbeta enhancer (Ebeta).Nucleic acids research · 2004Article
- Stimulation of Tat-independent transcriptional processivity from the HIV-1 LTR promoter by matrix attachment regions.Nucleic acids research · 2003Article
- The transcription factor, Bright, and immunoglobulin heavy chain expression.Immunologic research · 2001Review
- Recombination and transcription of the endogenous Ig heavy chain locus is effected by the Ig heavy chain intronic enhancer core region in the absence of the matrix attachment regions.Proceedings of the National Academy of Sciences of the United States of America · 1999Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
In the accompanying report (C. F. Webb, C. Das, S. Eaton, K. Calame, and P. Tucker, Mol. Cell. Biol. 11:5197-5205, 1991), we characterize B-cell-specific protein-DNA interactions at -500 and -200 bp upstream of the mu immunoglobulin heavy chain promoter whose abundances were increased by interleukin-5 plus antigen. Because of the high A + T/G + C ratio of these sequences and the consistent findings by others that enhancer- and promoterlike regions are often located near matrix-associated regions, we asked whether these sequences might also be involved in binding to the nuclear matrix. Indeed, DNA fragments containing the -500 binding site were bound by nuclear matrix proteins. Furthermore, UV cross-linking studies showed that the DNA binding site for interleukin-5-plus-antigen-inducible proteins could also bind to proteins solubilized from the nuclear matrix. Nuclear matrix-associated sequences have also been demonstrated on either side of the intronic immunoglobulin heavy chain enhancer. Our data suggest a topological model by which interactions among proteins bound to the promoter and distal enhancer sequences might occur.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.